Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

被引：0
|
作者：
Satoshi Watanabe
Junta Tanaka
Takeshi Ota
Rie Kondo
Hiroshi Tanaka
Hiroshi Kagamu
Kosuke Ichikawa
Jun Koshio
Junko Baba
Takao Miyabayashi
Ichiei Narita
Hirohisa Yoshizawa
机构：
[1] Niigata University Medical and Dental Hospital,Department of Medicine (II)
[2] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
来源：
BMC Cancer | / 11卷
关键词：
Overall Survival; Gefitinib; Erlotinib; NSCLC Patient; Disease Control Rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Kimio Yonesaka
    Eiji Iwama
    Hidetoshi Hayashi
    Shinichiro Suzuki
    Ryoji Kato
    Satomi Watanabe
    Takayuki Takahama
    Junko Tanizaki
    Kaoru Tanaka
    Masayuki Takeda
    Kazuko Sakai
    Koichi Azuma
    Yasutaka Chiba
    Shinji Atagi
    Kazuto Nishio
    Isamu Okamoto
    Kazuhiko Nakagawa
    Scientific Reports, 9
  • [22] THE SYNTHETIC EFFECT OF AROMATASE INHIBITOR ANASTROZOLE IN COMBINATION WITH EGFR TYROSINE KINASE INHIBITOR GEFITINIB IN NON-SMALL CELL LUNG CANCER CELL LINES
    Shen, Lan
    Lu, Shun
    Zhang, Fei Y.
    Li, Ziming
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S724 - S725
  • [23] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Yonesaka, Kimio
    Iwama, Eiji
    Hayashi, Hidetoshi
    Suzuki, Shinichiro
    Kato, Ryoji
    Watanabe, Satomi
    Takahama, Takayuki
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Sakai, Kazuko
    Azuma, Koichi
    Chiba, Yasutaka
    Atagi, Shinji
    Nishio, Kazuto
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [24] The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
    Choi, Jin-Hyuk
    Choi, Yong Won
    Lee, Hyun Woo
    Kang, Seok Yun
    Jeong, Geum Sook
    Ahn, Mi Sun
    Oh, Young-Taek
    Noh, O. Kyu
    Kim, Se-Hyuk
    Roh, Tae Hoon
    Sheen, Seung Soo
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (02): : 434 - 443
  • [25] Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Igawa, S.
    Sato, Y.
    Kusuhara, S.
    Harada, S.
    Shirasawa, M.
    Kurahayashi, S.
    Okuma, Y.
    Sugimoto, A.
    Sugita, K.
    Nakahara, Y.
    Otani, S.
    Fukui, T.
    Yokoba, M.
    Mitsufuji, H.
    Kubota, M.
    Katagiri, M.
    Sasaki, J.
    Masuda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2126 - S2127
  • [26] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [27] Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
    Zhong, Hua
    Zhang, Xueyan
    Tian, Panwen
    Chu, Tianqing
    Guo, Qisen
    Yu, Xinmin
    Yu, Zhuang
    Li, Yalun
    Chen, Lijuan
    Liu, Jie
    Zhang, Yan
    Guan, Yan
    Shi, Xun
    Wang, Jing
    Zhao, Yanqiu
    Han, Baohui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (08)
  • [28] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Giandomenico Roviello
    Laura Zanotti
    Maria Rosa Cappelletti
    Angela Gobbi
    Martina Dester
    Giovanni Paganini
    Chiara Pacifico
    Daniele Generali
    Raheleh Roudi
    Clinical and Experimental Medicine, 2018, 18 : 15 - 20
  • [29] Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
    Liao, Bin-Chi
    Bai, Ya-Ying
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Lin, Shu-Yung
    Lee, Yee-Fan
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Chang, Yeun-Chung
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    Yang, Pan-Chyr
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (04) : 326 - 331
  • [30] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
    Masuda, Takeshi
    Miura, Satoru
    Sato, Yuki
    Tachihara, Motoko
    Bessho, Akihiro
    Nakamura, Atsushi
    Miyawaki, Taichi
    Yoshimine, Kohei
    Mori, Masahide
    Shiraishi, Hideaki
    Hamai, Kosuke
    Haratani, Koji
    Maeda, Sumiko
    Tabata, Eriko
    Kitagawa, Chiyoe
    Tanizaki, Junko
    Imai, Takumi
    Nogami, Shohei
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Hattori, Noboru
    SCIENTIFIC REPORTS, 2023, 13 (01)
12345